Quick Answer
Acrivon Therapeutics, Inc. reported Operating Income of -$84.11 million for fiscal year 2025.
Acrivon Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$84.11M | +5.7% |
| 2024 | -$89.20M | -32.9% |
| 2023 | -$67.10M | -105.5% |
| 2022 | -$32.66M | -101.8% |
| 2021 | -$16.18M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$19.69M | +21.7% | +13.1% |
| June 30, 2025 | -$22.65M | -5.7% | -4.6% |
| March 31, 2025 | -$21.66M | -22.6% | +13.8% |
| September 30, 2024 | -$25.14M | -55.8% | -17.3% |
| June 30, 2024 | -$21.44M | -38.1% | -21.3% |
| March 31, 2024 | -$17.67M | -22.8% | -9.5% |
| September 30, 2023 | -$16.14M | -68.5% | -4.0% |
| June 30, 2023 | -$15.52M | -161.9% | -7.8% |
- Acrivon Therapeutics, Inc. showed an increase of +5.7% in Operating Income compared to the prior fiscal year.
- Over the 2021–2025 period, Acrivon Therapeutics, Inc.’s operating income has declined by 419.7% (from -$16.18 million to -$84.11 million).
- The most recent figure is from Acrivon Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: